Eriksson, Jan W.

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care

Diabetes Treatment and ManagementPeptidase Inhibition and Analysis

Cited by 421

Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study

Eriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 396

Emerging role of SGLT-2 inhibitors for the treatment of obesity

Pereira, M. J., & Eriksson, J. W. (2019) · Drugs

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 342

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study

Dandona, P., Mathieu, C., Phillip, M., Hansen, L., Tschöpe, D., Thorén, F., Xu, J., Langkilde, A. M., DEPICT-1 Investigators, Proietto, J., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 243

The incidence of Type I diabetes has not increased but shifted to a younger age at diagnosis in the 0–34 years group in Sweden 1983 to 1998

and the Swedish Childhood Diabetes Study Group, Pundziute-Lyckå, A., Dahlquist, G., Nyström, L., Arnqvist, H., Björk, E., Blohmé, G., Bolinder, J., Eriksson, J., Sundkvist, G., et al. (2002) · Diabetologia

Diabetes and associated disordersDiabetes Management and Research

Cited by 234

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study

Birkeland, K. I., Bodegard, J., Eriksson, J. W., Norhammar, A., Haller, H., Linssen, G. C. M., Banerjee, A., Thuresson, M., Okami, S., Garal‐Pantaler, E., et al. (2020) · Diabetes, Obesity and Metabolism

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 223

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: Amultinational observational study

Persson, F., Nyström, T., Jørgensen, M. E., Carstensen, B., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Eriksson, J. W., Norhammar, A., et al. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 212

Gender differences and temporal variation in the incidence of type 1 diabetes: results of 8012 cases in the nationwide Diabetes Incidence Study in Sweden 1983–2002

Östman, J., Lönnberg, G., Arnqvist, H. J., Blohmé, G., Bolinder, J., Schnell, A. E., Eriksson, J. W., Gudbjörnsdottir, S., Sundkvist, G., & Nyström, L. (2008) · Journal of Internal Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 147

Dapagliflozin once‐daily and exenatide once‐weekly dual therapy: A 24‐week randomized, placebo‐controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes

Lundkvist, P., Sjöström, C. D., Amini, S., Pereira, M. J., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 108

Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial

Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 104

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year

Lundkvist, P., Pereira, M. J., Katsogiannos, P., Sjöström, C. D., Johnsson, E., & Eriksson, J. W. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 72

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes.

Littorin, B., Sundkvist, G., Hagopian, W., Landin-Olsson, M., Lernmark, A., Ostman, J., Arnqvist, H. J., Blohmé, G., Bolinder, J., Eriksson, J. W., et al. (1999) · Diabetes Care

Diabetes and associated disordersDiabetes Management and Research

Cited by 72

Altered expression of aromatase and estrogen receptors in adipose tissue from men with obesity or type 2 diabetes

Ahmed, F., Hetty, S., Laterveer, R., Surucu, E. B., Mathioudaki, A., Hornbrinck, E., Patsoukaki, V., Olausson, J., Sundbom, M., Svensson, M. K., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism

Estrogen and related hormone effectsAdipokines, Inflammation, and Metabolic Diseases

Cited by 40